 Connection
Virginia Borges to Retrospective Studies
This is a "connection" page, showing publications Virginia Borges has written about Retrospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.179 |
|
|
|
-
Shagisultanova E, Parris H, Liu L, Giangiuli S, Gao D, Diamond JR, Acharya-Leon R, Kabos P, Borges VF. Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. Clin Breast Cancer. 2025 Oct; 25(7):643-649.e1.
Score: 0.063
-
Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, Urquhart A, Schedin P, Borges VF. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):549-59.
Score: 0.027
-
Morganti S, Kim SE, Jin Q, Cha J, Zeigler JE, Newman AB, Kirkner GJ, Snow C, Zheng Y, Vincuilla J, Parker T, Buehler RM, Bychkovsky BL, Dibble KE, Sella T, Ruddy KJ, Rosenberg SM, Collins LC, Peppercorn J, Schapira L, Borges VF, Guzman-Arocho YD, Come SE, Warner E, Poorvu PD, Lambertini M, Curigliano G, Hughes ME, Mittendorf EA, King TA, Lin NU, Garber JE, Tayob N, Tolaney SM, Partridge AH, Lynce F. Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies. JNCI Cancer Spectr. 2026 Jul 07; 10(4).
Score: 0.017
-
Sakamoto MR, Eguchi M, Azelby CM, Diamond JR, Fisher CM, Borges VF, Bradley CJ, Kabos P. New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer. J Natl Compr Canc Netw. 2021 01 06; 19(1):29-38.
Score: 0.011
-
Sella T, Gelber SI, Poorvu PD, Kim HJ, Dominici L, Guzman-Arocho YD, Collins L, Ruddy KJ, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Snow C, Jakubowski DM, Russell CA, Winer EP, Rosenberg SM, Partridge AH. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2021 Feb; 186(1):157-165.
Score: 0.011
-
Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 12; 9(23):8801-8808.
Score: 0.011
-
Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503.
Score: 0.009
-
Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 06 10; 34(17):1995-2002.
Score: 0.008
-
Rocha MS, Andrade LA, Ferraz HB, Borges V. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease]. Arq Neuropsiquiatr. 1995 Dec; 53(4):737-42.
Score: 0.008
-
Borges V, Ferraz HB, de Andrade LA. [Essential tremor: clinical characterization in a sample of 176 patients]. Arq Neuropsiquiatr. 1994 Jun; 52(2):161-5.
Score: 0.007
-
Costa J, Ortiz-Ibañez K, Salerni G, Borges V, Carrera C, Puig S, Malvehy J. Dermoscopic patterns of melanoma metastases: interobserver consistency and accuracy for metastasis recognition. Br J Dermatol. 2013 Jul; 169(1):91-9.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|